Following EPO presentation of the minutes of the Oral Proceedings earlier today, We have been in contact with BioPorto.
According to the information BioPorto have received – a wrritten explanation on the reasoning of the OD is under way. EPO have informed BioPorto that the explanatory note is to be received sometime next week.
BioPorto has promised [...]
As you are all painfully aware of, EPO (European Patent Organisation) held Oral Proceedings on the fate of the courted NGAL cutoff-patent, on Feb. the 8th
Now – after ONLY three months (sic !) the details of the proceedings are made public.
All -the relevant documents can be found here.
It is, however, pretty much as what we [...]
Tjen penge på dine- og andres indlæg på MedicoInvestor.com
By admin On 15. May 2012 · 1828Leave a Commenthttp%3A%2F%2Fmedicoinvestor.com%2Ftjen-penge-pa-dit-og-andres-indlaeg-pa-medicoinvestor-com.htmlTjen+penge+p%C3%A5+dine-+og+andres+indl%C3%A6g+p%C3%A5+MedicoInvestor.com2012-05-15+08%3A07%3A05adminhttp%3A%2F%2Fmedicoinvestor.com%2F%3Fp%3D1828 · In MedicoInvestor
Ny feature på MedicoInvestor.com
Kære alle medlemmer.
Vi har nu gjort det muligt for dig at tjene penge på dine indlæg.
Har du nogensinde siddet og skrevet et indlæg på flere sider, og efter at have
postet har siddet med en lidt tom fornemmelse over kun at modtage Thumbs Up, og
klap på skulderen for dit gode indlæg?
På MedicoInvestor.com har [...]
Dandrit strengthens its European Patent base. This company has potential of surpassing rival Dendreon in the field of Cancer Vaccine I kid you not….
Dandrit A/s is through merger of cash-rich DKTI A/S securing a financial platform for expansion and a platform on the Copenhagen Stock Exchange. Ongoing talks – that were first publicized late 2011 [...]
In relation to the former post, stating that an evaluation of the The NGAL Test on BC 5822, had been carried out, the full text of the complete evaluation is now avaliable. Its showtime Folks, its: The NGAL Test versus the Rest: In short - the conclusion is – that the NGAL Test is immensely superior [...]
Abbott takes on one of the many challenges Doctors face when dealing with AKI, new medicine helps prevent AKI stemming from cardiac surgery
http://www.renalbusiness.com/news/2012/05/abbott-pays-cash-for-aki-drug.aspx
Quote:
“ABBOTT PARK, Ill.—Still wheeling and dealing on the road up to its spinoff this year, the drug arm of Abbott Laboratories has snagged Action Pharma’s Phase IIb program for acute kidney injury (AKI) [...]
Nu er der lige kommet WK data for marts på 23 millioner, så laver lige en update af mit tidligere indlæg:
——————————————————-
Hermed følger lige en optakt til Spectrum 1. kvartalsrapport som de kommer med torsdag den 26/4 2012. Jeg vil lige understreje at der er tale om min egen analyse, baseret på forventninger, som jeg så [...]
Kampagnetilbud på Aktieugebrevet
Popular entries
Bioporto news- Development of Annual General Meeting 17. April 2012
- Orientering om forløb af den ordinære generalforsamling i BioPorto A/S 17. April 2012
- Indkaldelse til ordinær generalforsamling 22. March 2012
Recent Posts
- EPO, Oral Proceedings / NGAL cutoff-patent (II)
- EPO, Oral Proceedings / NGAL cutoff-patent
- Tjen penge på dine- og andres indlæg på MedicoInvestor.com
- Dandrit – a new Dendreon ? Sure looks like it !
- Complete evaluation of NGAL-test on bc 5822
- Abbott buys new medicine to help prevent AKI
- Update: Optakt Spectrum Q1
- NGAL-test – a marker for anemia ?
- Optakt til Spectrum Q1 regnskab 26/4 2012
- An inspiring look at AKI (NGAL versus the rest)
- Spectrum chart
- 2014 – a threat for Bioporto, the NGAL-patent or the NGAL-test ??
